Skip to Main Content

Author Details

Jie Zhang
2016
17
11
PMIDPaper TitleJournal TitlePublished Year
34883044NUMB as a Therapeutic Target for Melanoma.J Invest Dermatol2022
34937742Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.J Immunother Cancer2021
34011536Dichotomous and stable gamma delta T-cell number and function in healthy individuals.Journal for ImmunoTherapy of Cancer2021
34304249Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Oncogene2021
33429424DeepCNV: a deep learning approach for authenticating copy number variations.Brief Bioinform2021
32908002Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade.Sci Transl Med2020
30858377Author Correction: Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesis.Nat Commun2019
30532003Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Nature2019
30575721Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesis.Nat Commun2018
28927893MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression.J Invest Dermatol2018
28606508Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.International Journal of Pharmaceutics2017
28953887PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Nature2017
28969964Localized microbubble cavitation-based antivascular therapy for improving HCC treatment response to radiotherapy.Cancer Letters2017
28928360Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.Nat Commun2017
27448973PIM kinases as therapeutic targets against advanced melanoma.Oncotarget2016
27043285Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.J Clin Invest2016
26846625RGD and polyhistidine tumor homing peptides potentiates the action of human Maspin as an antineoplastic candidate.Applied Microbiology and Biotechnology2016
  • 1 - 17 of 17

Recommended Authors

Collaborators

Zhi Wei
Co-authored papers 12
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers 11
Gao Zhang
Co-authored papers 10
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 7
Yiling Lu
Co-authored papers 6
Chaoran Cheng
Co-authored papers 4
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Co-authored papers 3
Jennifer A Wargo
Co-authored papers 2
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Richard A Sturm
Frazer Institute, The University of Queensland, Dermatology Research Centre
Co-authored papers 1
Dong Wang
Co-authored papers 1
Richard A Scolyer
Co-authored papers 1
Yan Sun
Co-authored papers 1
Leandro C Hermida
University of Pittsburgh
Co-authored papers 1
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 1
Bin Wu
University of Pennsylvania
Co-authored papers 1
Lei He
Co-authored papers 1
Carl H June
University of Pennsylvania Department of Pathology & Laboratory Medicine
Co-authored papers 1
Fei Ning
Co-authored papers 1
Wei Wang
IBM Thomas J Watson Research Center, University of California Los Angeles, University of North Carolina at Chapel Hill
Co-authored papers 1
Haiteng Deng
Co-authored papers 1
Zhisong Wang
Co-authored papers 1
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Xiaoyu Hu
Co-authored papers 1
Peter M Krawitz
Institute for Genomic Statistics and Bioinformatics, University of Bonn
Co-authored papers 1
Zhenda Wang
Co-authored papers 1
Jingwen Si
Co-authored papers 1
David E Fisher
Cutaneous Biology Research Center, Mass. General Hospital, Harvard Medical School
Co-authored papers 1
Yanyi Huang
Co-authored papers 1
Wei Wang
Co-authored papers 1
Release 1.2